 |
| Nebulizers - Long Acting Beta Agonists - Documentation Guidance The Nebulizers local coverage determination (LCD) stipulates that for coverage of long-acting beta agonist (LABA) formulations the following criterion must be met: It is medically necessary to administer formoterol (J7606) or arformoterol (J7605) for the management of chronic obstructive pulmonary disease (ICD-9 diagnosis codes 491.0-492.8, 496) and the patient has a documented history of routine use of at least four doses per day of an FDA-approved albuterol or metaproterenol inhalation solution or at least three doses per day of an FDA-approved levalbuterol inhalation solution. Suppliers have inquired about how to document the "history of routine use" and the time required to be on a short acting beta agonist (SABA) before converting to formoterol or arformoterol. The supplier's records should reflect that the beneficiary has used SABA therapy at the frequencies listed in the coverage criteria for a period of three (3) months. Suppliers should refer to the Nebulizer LCD for further information about coverage, coding and documentation requirements. |
| Remember! National Government Services' Jurisdiction B DME MAC List Serve is for out going messages only. Please do not respond back to messages as your response will not be answered, as this is not an authorized mode of communication at this time, Thank you! CONFIDENTIALITY NOTICE: This E-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply E-mail and destroy all copies of the original message. To unsubscribe/change profile: click here. |
Email list management powered by http://MailerMailer.com
Posts
